Skip to main content
Home
Issues
2024
November 2024 Vol 17, Payers' Guide to FDA Updates
2023
December 2023 Vol 16, Payers' Guide to FDA Updates
September 2023 Vol 16, Payers' Guide to FDA Updates
June 2023 - Vol 16 No 1
Issue Archive
Topics
Conference Correspondent
ESMO 2024 - Small Cell Lung Cancer
EHA 2024 – Wrap-Up: Myelodysplastic Syndrome
ASCO 2024 – Wrap-Up: Myelodysplastic Syndrome
Multimedia
Videos
Interview with the Innovators
Editorial Board
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Process
Advertising Policy
Subscribe
Home
Issues
2024
November 2024 Vol 17, Payers' Guide to FDA Updates
2023
December 2023 Vol 16, Payers' Guide to FDA Updates
September 2023 Vol 16, Payers' Guide to FDA Updates
June 2023 - Vol 16 No 1
Issue Archive
Topics
Conference Correspondent
ESMO 2024 - Small Cell Lung Cancer
EHA 2024 – Wrap-Up: Myelodysplastic Syndrome
ASCO 2024 – Wrap-Up: Myelodysplastic Syndrome
Multimedia
Videos
Interview with the Innovators
Editorial Board
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Process
Advertising Policy
Jeffrey D. Dunn, PharmD, MBA
Senior Vice President,
VRx Pharmacy Services,
Salt Lake City, UT
Senior Vice President, VRx Pharmacy Services, Salt Lake City, UT
Authored Items
Helping Patients Cope with Agitation: The Role of Pharmacists and Payers
Jeffrey D. Dunn, PharmD, MBA
Faculty Perspectives: Coping with Agitation Associated with Schizophrenia and Bipolar Disorder: How Can Healthcare Professionals Help Their Patients?
Addressing the Challenges of Treating Schizophrenia and Bipolar Disorder
Jeffrey D. Dunn, PharmD, MBA
Faculty Perspectives: The Spectrum of Agitation Associated with Schizophrenia and Bipolar Disorder
Impact of Glycemic Control on Healthcare Resource Utilization and Costs of Type 2 Diabetes: Current and Future Pharmacologic Approaches to Improving Outcomes
Mary Ann Banerji, MD, FACP
,
Jeffrey D. Dunn, PharmD, MBA
,
Jeffrey A. Bourret, PharmD
September 2013, Vol 6, No 7
in
Practice Management
Last modified: October 4, 2013